| [1] |
曹毛毛，陈万青．GLOBOCAN 2020全球癌症统计数据解读[J/CD]．中国医学前沿杂志(电子版)，2021，13(3)：63-69.
|
| [2] |
乳腺癌中西医结合诊疗共识[J/CD]．中国医学前沿杂志(电子版)，2021，13(7)：44-64.
|
| [3] |
Tokunaga R, Naseem M, Lo JH, et al. B cell and B cell-related pathways for novel cancer treatments[J]. Cancer Treat Rev，2019, 73: 10-19.
|
| [4] |
Chen Y, Wang L, Liu H, et al. PET imaging on dynamic metabolic changes after combination therapy of paclitaxel and the traditional Chinese medicine in breast bancer-bearing mice[J]. Mol Imaging Biol，2018，20(2)：309-317.
|
| [5] |
Chen Y, Wu H, Wang X, et al. Huaier granule extract inhibit the proliferation and metastasis of lung cancer cells through down-regulation of MTDH, JAK2/STAT3 and MAPK signaling pathways[J]. Biomed Pharmacother，2018，101：311-321.
|
| [6] |
Wilson BE, Gorrini C, Cescon DW. Breast cancer immune microenvironment: from pre-clinical models to clinical therapies[J]．Breast Cancer Res Treat，2022，191(2)：257-267.
|
| [7] |
Baxevanis CN, Fortis SP, Perez SA. The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies[J]. Semin Cancer Biol，2021，72：76-89.
|
| [8] |
O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol，2019，16(3)：151-167.
|
| [9] |
Emens LA, Adams S, Cimino-Mathews A, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer [J]. J Immunother Cancer，2021，9(8)：e002597.
|
| [10] |
Fang W, Zhou T, Shi H, et al. Correction to: progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8＋ T cell exclusion[J]. J Exp Clin Cancer Res，2022，41(1)：93.
|
| [11] |
Van Kooyk Y, Appelmelk B, Geijtenbeek TB. A fatal attraction: Mycobacterium tuberculosis and HIV-1 target DC-SIGN to escape immune surveillance[J]. Trends Mol Med，2003，9(4)：153-159.
|
| [12] |
Galluzzi L, Humeau J, Buqué A, et al.Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors[J]. Nat Rev Clin Oncol，2020，17(12)：725-741.
|
| [13] |
Hatic H, Sampat D, Goyal G. Immune checkpoint inhibitors in lymphoma: challenges and opportunities[J]. Ann Transl Med，2021，9(12)：1037.
|
| [14] |
鲁明骞，孔庆志，卢宏达，等．槐耳颗粒联合化疗对乳腺癌患者术后机体免疫功能的影响[J]．辽宁中医杂志，2017，44(5)：966-969.
|
| [15] |
Schmid P, Cruz C, Braiteh FS，et al.Atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analyses[J]．Cancer Res，2017，77：13.
|
| [16] |
Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study[J]. JAMA Oncol，2019，5(1)：74-82.
|
| [17] |
Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study[J]. Breast Cancer Res Treat，2018，167(3)：671-686.
|
| [18] |
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med，2018，379(22)：2108-2121.
|
| [19] |
Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer[J]. J Natl Compr Canc Netw, 2020，18(4)：479-489.
|
| [20] |
Huang L, Rong Y, Tang X, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer[J]. Mol Cancer，2022，21(1)：45.
|
| [21] |
Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy[J]. Nat Rev Immunol，2020，20(1)：7-24.
|
| [22] |
Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma[J]. J Clin Oncol，2015，33(25)：2780-2788.
|
| [23] |
Zhu SY, Yu KD. Breast cancer vaccines: disappointing or promising？[J]. Front Immunol, 2022，13：828386.
|
| [24] |
Roux C, Jafari SM, Shinde R, et al.Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1[J]. Proc Natl Acad Sci U S A，2019，116(10)：4326-4335.
|
| [25] |
Yang L, Zhang Y, Zhang Y, et al. Live macrophage-delivered doxorubicin-loaded liposomes effectively treat triple-negative breast cancer[J]. ACS Nano，2022，16(6)：9799-9809.
|
| [26] |
Woods DM, Ramakrishnan R, Laino AS, et al. Decreased suppression and increased phosphorylated STAT3 in regulatory T cells are associated with benefit from adjuvant PD-1 blockade in resected metastatic melanoma[J]. Clin Cancer Res，2018，24(24)：6236-6247.
|
| [27] |
Zhang X, Zheng K, Li C, et al. Nobiletin inhibits invasion via inhibiting AKT/GSK3β/β-catenin signaling pathway in Slug-expressing glioma cells[J]. Oncol Rep，2017，37(5)：2847-2856.
|
| [28] |
Roscigno G, Cirella A, Affinito A, et al. miR-216a acts as a negative regulator of breast cancer by modulating stemness properties and tumor microenvironment[J]. Int J Mol Sci，2020，21(7)：2313.
|
| [29] |
尹剑桥，李午生，韩思佳，等．槐耳颗粒联合TEC新辅助化疗对中晚期乳腺癌患者疾病控制率及血清HER2-ECD、TAP水平的影响[J]．中国医师杂志，2021，23(4)：568-572.
|
| [30] |
雷姗姗，王映，顾晓文，等．槐耳颗粒在三阴性乳腺癌术后辅助治疗的临床研究[J]．中国普通外科杂志，2016，25(5)：717-723.
|
| [31] |
鲁明骞，孔庆志，卢宏达，等．槐耳颗粒联合化疗对乳腺癌患者术后机体免疫功能的影响[J]．辽宁中医杂志，2017，44(5)：966-969.
|
| [32] |
Wang S, Wang X, Zhou X, et al. DC-CIK as a widely applicable cancer immunotherapy[J]. Expert Opin Biol Ther, 2020，20(6)：601-607.
|
| [33] |
Pan J, Jiang Z, Wu D, et al. Huaier extractum promotes dendritic cells maturation and favors them to induce Th1 immune response: one of the mechanisms underlying its anti-tumor activity[J]. Integr Cancer Ther, 2020，19：1534735420946830.
|
| [34] |
Li C, Wang X, Chen T, et al. Huaier induces immunogenic cell death via CircCLASP1/PKR/eIF2αsignaling pathway in triple negative breast cancer[J]. Front Cell Dev Biol，2022，10：913824.
|
| [35] |
Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment[J]. Int J Mol Sci，2021，22(13)：6995.
|
| [36] |
Munir MT, Kay MK, Kang MH, et al. Tumor-associated macrophages as multifaceted regulators of breast tumor growth[J]. Int J Mol Sci，2021，22(12)：6526.
|
| [37] |
Huang XY, Zhang PF, Wei CY, et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis[J]. Mol Cancer，2020，19(1)：92.
|
| [38] |
Li Y, Qi W, Song X, et al. Huaier extract suppresses breast cancer via regulating tumor-associated macrophages[J]. Sci Rep，2016，6：20049.
|
| [39] |
Li C, Wang X, Chen T, et al. Trametes robiniophila Murr in the treatment of breast cancer[J]. Biomed Pharmacother，2020，128：110 254.
|